Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

Centocor Ortho Biotech

Pharmaceutical intelligence for Centocor Ortho Biotech with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
0
Assets
1

Recent signals(2)

RegulatoryJuly 27, 2026

FDA Accepts Supplement for STELARA (Ustekinumab) by Centocor Ortho Biotech

The FDA has accepted a supplemental application for STELARA (ustekinumab) from Centocor Ortho Biotech.

RegulatoryJuly 18, 2026

FDA Accepts Supplementary Application for STELARA by Centocor Ortho Biotech

The FDA has accepted a supplementary application for STELARA, indicating ongoing development and potential label expansion.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(2)

RegulatoryJuly 27, 2026

FDA Accepts Supplement for STELARA (Ustekinumab) by Centocor Ortho Biotech

The FDA has accepted a supplemental application for STELARA (ustekinumab) from Centocor Ortho Biotech.

RegulatoryJuly 18, 2026

FDA Accepts Supplementary Application for STELARA by Centocor Ortho Biotech

The FDA has accepted a supplementary application for STELARA, indicating ongoing development and potential label expansion.

Clinical activity

No signals indexed for this entity yet.

Competitive activity

No signals indexed for this entity yet.

Assets

STELARA →

Therapeutic areas

23 →
23 Inhibitor →
IL-12 →
Immunology →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.